U.S. Animal Model Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Animal Model Market
- ✓Market Size 2024: USD 1.42 billion
- ✓Market Size 2032: USD 2.06 billion
- ✓CAGR: 4.7%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Supply, Pilot Alternatives: Pharmaceutical procurement directors should secure multi-year rodent supply agreements with Charles River Laboratories and The Jackson Laboratory before the FY2026 appropriations cycle concludes. They should also pilot organ-on-chip validation by Q1 2027, since FDA now accepts non-animal evidence.
Animal Models in the United States: Market Overview
The U.S. animal model market, which supplies bred rodents, non-human primates, dogs, and genetically engineered lines to drug developers, contract research organizations, and academic laboratories, was valued at approximately USD 1.42 billion in 2024 on an analyst basis. Its structure is shaped by federal law more than by open-market demand. The Animal Welfare Act of 1966 governs most mammals but expressly excludes mice and rats bred for research, so the bulk of rodent volume falls under the Public Health Service Policy administered by NIH's Office of Laboratory Animal Welfare.
Government has been the dominant force on the demand side. NIH and the seven National Primate Research Centers anchor non-human primate supply, while FDA expectations for preclinical toxicology set pharmaceutical demand. Private suppliers have led on rodent genetics and commercial breeding, with The Jackson Laboratory and Charles River Laboratories building global catalogues of standardized strains. Government rules set the volume floor, and private firms capture margin on defined, traceable models.
Policy-Driven Growth in U.S. Animal Models
First, the FDA Modernization Act 2.0, signed on 29 December 2022, removed the statutory mandate that drug sponsors test in animals before first-in-human trials. This widened regulatory room for alternatives while creating demand for validated comparative models. Second, the Good Laboratory Practice regulations at 21 CFR Part 58 still require animal toxicology studies for most investigational new drug packages, sustaining recurring demand for rodent and dog studies across pharmaceutical and contract research pipelines.
Third, NIH's Office of Research Infrastructure Programs funds the seven National Primate Research Centers, and NIH's annual appropriation of roughly USD 47 billion sustains grant-funded model purchases by universities. Each grant dollar passes through IACUC-approved protocols, so budget allocations translate directly into animal purchases within the approval cycle. This funding chain is the core growth mechanism for research-grade supply.
Regulatory Barriers and Compliance Costs
The USDA Animal and Plant Health Inspection Service, through its Animal Care unit, licenses dealers and exhibitors under 9 CFR Part 2 and sets housing and handling standards in 9 CFR Part 3. Class A breeder and Class B dealer licenses require unannounced inspections, veterinary care plans, and detailed recordkeeping. Facilities that receive critical violations face enforcement escalation, and remediation can halt colony sales for months, a delay suppliers price into long-term contracts.
NIH's PHS Policy requires an Institutional Animal Care and Use Committee to approve every protocol, and OLAW conducts assurance reviews of institutions. Non-human primate imports add a separate layer: the CDC import permit program under 42 CFR Part 71 extends procurement timelines beyond USDA requirements. The 2022 U.S. Fish and Wildlife Service listing of all chimpanzees as endangered under the Endangered Species Act has tightened permitting for chimpanzee research.
Policy-Created Opportunities in U.S. Animal Models
NIH's Complement-ARIE program, administered through the Common Fund, funds standardized organoid and human-tissue platforms. This creates a procurement lane for suppliers able to certify reproducible human-derived models. Champions Oncology, which supplies patient-derived xenograft models, is positioned to deliver humanized immunodeficient mouse lines that sit between full animal and non-animal assays.
The FDA's ISTAND pilot program, which accepted the Emulate Liver-Chip into its qualification pathway in 2024, opens a route for organ-on-chip systems to become qualified drug development tools. Suppliers of genetically defined knockout and humanized rodent colonies, including Cyagen Biosciences and Taconic Biosciences, can generate validation datasets that feed into ISTAND review. Early movers will secure reference positions before qualification standards harden.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 1.42 billion |
| Market Size 2032 | USD 2.06 billion |
| Growth Rate (CAGR) | 4.7% |
| Most Critical Decision Factor | Regulatory acceptance of non-animal alternatives under FDA Modernization Act 2.0 |
| Largest Region | Northeast and Mid-Atlantic (Massachusetts, New Jersey, Pennsylvania) |
| Competitive Structure | Consolidated, with the top five suppliers holding the majority of revenue |
Leading Market Participants
- Charles River Laboratories
- The Jackson Laboratory
- Inotiv
- Taconic Biosciences
- Labcorp Drug Development
- Crown Bioscience
- Cyagen Biosciences
- Marshall BioResources
- Ridglan Farms
- Champions Oncology
Regulatory and Policy Environment in the United States
The primary legislation is the Animal Welfare Act (7 U.S.C. §2131 et seq.), enforced by USDA APHIS Animal Care through 9 CFR Parts 2 and 3. Research use is further governed by the PHS Policy on Humane Care and Use of Laboratory Animals, enforced by NIH OLAW, and by the Federal Food, Drug, and Cosmetic Act, which FDA enforces alongside 21 CFR Part 58 on Good Laboratory Practice. Key compliance requirements include IACUC approval, veterinary oversight, facility registration, and institutional biosafety review under the NIH Guidelines for recombinant nucleic acid work.
Upcoming changes center on FDA's April 2025 roadmap, which targets phasing down animal testing for monoclonal antibodies first, and on the pending FDA Modernization Act 3.0 in the 119th Congress. NIH has created the Office of Research Innovation, Validation, and Application to prioritize human-based methods. Compared with regional peers, the U.S. framework is more permissive than the EU, where Directive 2010/63/EU covers all live vertebrates including mice, and the UK's Animals (Scientific Procedures) Act 1986 requires project licensing for each procedure.
Long-Term Policy Outlook for U.S. Animal Models
By 2032, FDA is expected to have qualified additional organ-on-chip and organoid tools through ISTAND, reducing animal use for monoclonal antibody and selected biologic programs. Small-molecule toxicology will continue to require rodent and dog data under 21 CFR Part 58, so volumes in those categories will persist. Non-human primate demand will decline as federal funding prioritizes alternatives and chimpanzee research remains restricted under the Endangered Species Act.
NIH's restructuring under the new validation office will shift grant allocations toward human-derived platforms and genetically defined models, raising the value per animal supplied. Revisions to the PHS Policy and possible statutory updates under FDA Modernization Act 3.0 will tighten reporting requirements for institutions. These changes will reward suppliers with validated quality systems and consolidate the market around the largest providers, supporting growth to approximately USD 2.06 billion by 2032.
Frequently Asked Questions
Market Segmentation
- Mouse Models
- Rat Models
- Non-Human Primates
- Canine Models
- Zebrafish and Other Models
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Nonprofit Research Institutes
- Government Research Agencies
- Drug Discovery and Efficacy
- Toxicology and Safety Assessment
- Basic Biomedical Research
- Vaccine and Biologics Testing
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.